KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study.

Christopher J Edwards, Gerhard Krönke, Jérôme Avouac, Zhanguo Li, Fabrizio Conti, Alejandro Balsa, Daojun Mo, Ewa Haladyj, Peter Fischer, Masaru Tanaka, Yasushi Takita, Kohei Hagimori, Tsutomu Takeuchi

J Rheumatol 52(4) 316-322

PMID39814441
PMCID-
DOI10.3899/jrheum.2024-0906
发表日期2025-01-15
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

OBJECTIVE: This study examined the effect of dose step-down in patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib 4 mg once daily for up to 96 weeks. METHODS: Patients who completed a baricitinib phase III study could enter a long-term extension (LTE). In the LTE, patients who received baricitinib 4 mg for ≥ 15 months and maintained Clinical Disease Activity Index (CDAI) low disease activity (LDA) or remission (REM) were blindly randomized to continue with 4 mg or taper to 2 mg. If needed, 2-mg-treated patients could be rescued to 4 mg, and 4-mg-treated patients could be rescued by adding or increasing conventional synthetic disease-modifying antirheumatic drugs. Efficacy and safety were assessed through 96 weeks. Nonresponder imputation (NRI), considering rescued or discontinued patients as nonresponders, was used for CDAI response analyses. RESULTS: At 96 weeks, most patients maintained LDA in both 2-mg and 4-mg arms, with a lower maintenance rate in the 2-mg than the 4-mg group (NRI 59.9% and 70.2%, respectively). Patients maintained REM in the 2-mg and 4-mg arms at 30.8% and 36.6%, respectively. Rescue rates were 14.7% for baricitinib 4 mg and 22.5% for 2 mg. Of 112 patients who lost LDA in the 2-mg arm and were rescued to 4 mg, 76.2% and 75.6% achieved LDA again at 12 and 24 weeks postrescue, respectively. CONCLUSION: In a randomized, blinded, phase III LTE study, maintenance of disease control following induction of sustained LDA/REM with baricitinib 4 mg was greater with continued 4 mg than after tapering to 2 mg. Nonetheless, 76% of patients tapered to 2 mg could maintain LDA/REM or recapture with return to 4 mg, if needed.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。